Citadel Advisors
XDNA

Citadel Advisors’s Strategic Trust Kelly CRISPR & Gene Editing Technology ETF XDNA Stock Holding History

Citadel Advisors’s Portfolio XDNA Stock Details XDNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-15,449
Closed -$137K – 15561
2023
Q1 		$137K Sell
15,449
-7,307
-32% -$74.7K ﹤0.01% 10785
2022
Q4 		$226K Sell
22,756
-1,455
-6% -$16.3K ﹤0.01% 9899
2022
Q3 		$284K Buy
+24,211
New +$306K ﹤0.01% 9706

Citadel Advisors's XDNA Position: Q2 2023 in Review

Citadel Advisors sold out of Strategic Trust Kelly CRISPR & Gene Editing Technology ETF (XDNA) in Q2 2023, closing a stake of 15,449 shares — an estimated $137K sold.

Citadel Advisors first reported a position in XDNA in Q3 2022 and held it in 3 quarters. The position peaked at $284K in Q3 2022. 0 funds tracked by Wall St. Rank hold XDNA as of Q2 2023.

  • Citadel Advisors reported no remaining Strategic Trust Kelly CRISPR & Gene Editing Technology ETF position as of Q2 2023 after selling out during the quarter.
  • Citadel Advisors sold 15,449 Strategic Trust Kelly CRISPR & Gene Editing Technology ETF shares in Q2 2023, an estimated $137K.
  • Citadel Advisors first reported a position in Strategic Trust Kelly CRISPR & Gene Editing Technology ETF in Q3 2022 and held it in 3 quarters.
  • Citadel Advisors's Strategic Trust Kelly CRISPR & Gene Editing Technology ETF position peaked at $284K in Q3 2022.
  • 0 funds tracked by Wall St. Rank held Strategic Trust Kelly CRISPR & Gene Editing Technology ETF as of Q2 2023.

Based on Citadel Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.